Orchestra Biomed Hldgs Inc (OBIO)

$2.57 -0.05 (-1.91%)
Market Cap 99.32M
Revenue (ttm) 2.64M
Net Income (ttm) -61.02M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -2,311.36%
Debt to Equity Ratio 47.93
Volume 119,200
Avg Vol 291,480
Day's Range N/A - N/A
Shares Out 38.64M
Stochastic %K 4%
Beta 0.61
Analysts Strong Sell
Price Target $13.50

Company Profile

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications;...

Industry: Biotechnology
Sector: Healthcare
Phone: 215 862 5797
Address:
150 Union Square Drive, New Hope, United States
j03j03j06
j03j03j06 Sep. 12 at 9:57 AM
$OBIO Im tired of this shit. Swing but shit moves recently bro.
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:16 PM
G101SPM 8/26/2025, 8:02:32 AM $OBIO $2.65 bid. DAC (4) $3.38 / last $2.75 (8.5.25). EXIT $7.00.
0 · Reply
G101SPM
G101SPM Sep. 9 at 2:59 PM
G101SPM 8/8/2025, 7:25:33 AM $OBIO $2.69 bid. DAC (dollar average cos) (4) $3.38 / last $2.75 (8.75 (8.5.25). EXIT $7.00.
0 · Reply
G101SPM
G101SPM Sep. 9 at 2:51 PM
G101SPM 8/5/2025, 7:15:52 AM $OBIO $2.75 ask. BUY/ADD 3X to long position carries SPM 84.97 tag to $7.00 in midterm. DAC (dollar average cost includes this BUY). (4) $3.28.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 2:20 PM
$OBIO Great piece that accurately captures OBIO's current position. So if you want to refresh your understanding of OBIO or learn about OBIO for the first time, this is essential reading. https://beyondspx.com/quote/OBIO/orchestra-biomed-orchestrating-future-growth-through-breakthrough-technologies-and-strategic-alliances-nasdaq-obio#analysis
0 · Reply
estatebuyersmia
estatebuyersmia Sep. 5 at 10:54 AM
$OBIO REMEMBER IF ABCL OPENS ABOVE 4.20 WE ARE LOOKING AT A DEF MOVE TO 4.50. IF IT BREAKS 4.50, IT WILL TRY TO REACH 5.00
0 · Reply
sn0wball
sn0wball Sep. 5 at 10:53 AM
$OBIO https://finance.yahoo.com/news/orchestra-biomed-presents-avim-therapy-210000958.html
0 · Reply
BearishAlgo
BearishAlgo Sep. 4 at 11:19 PM
$OBIO
0 · Reply
YouVSYou
YouVSYou Sep. 4 at 11:02 PM
$TPVG tracking with $OBIO insider
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 4 at 10:17 PM
$OBIO been tweaking u on and off latly
0 · Reply
Latest News on OBIO
Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Sep 4, 2025, 5:00 PM EDT - 10 days ago

Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Aug 26, 2025, 7:30 AM EDT - 19 days ago

Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Aug 14, 2025, 8:00 AM EDT - 4 weeks ago

Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Aug 12, 2025, 8:14 AM EDT - 4 weeks ago

Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Aug 8, 2025, 7:00 AM EDT - 5 weeks ago

Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

Aug 5, 2025, 7:00 AM EDT - 5 weeks ago

Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Aug 1, 2025, 7:59 AM EDT - 6 weeks ago

Orchestra BioMed Announces Pricing of $40 Million Public Offering

Orchestra BioMed Announces Proposed Public Offering

Jul 31, 2025, 4:02 PM EDT - 6 weeks ago

Orchestra BioMed Announces Proposed Public Offering

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

Jul 31, 2025, 4:01 PM EDT - 6 weeks ago

Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed

LGND MDT

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Jun 18, 2025, 9:30 AM EDT - 3 months ago

Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

May 28, 2025, 7:20 AM EDT - 3 months ago

Orchestra BioMed: Two Best-In-Class Devices And Promising Partnerships

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

May 12, 2025, 4:28 PM EDT - 4 months ago

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

May 7, 2025, 8:30 AM EDT - 4 months ago

Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Apr 29, 2025, 9:00 AM EDT - 4 months ago

Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Apr 28, 2025, 4:30 PM EDT - 4 months ago

Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

Apr 23, 2025, 9:00 AM EDT - 5 months ago

Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting

MDT

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Apr 22, 2025, 7:00 AM EDT - 5 months ago

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Mar 31, 2025, 4:21 PM EDT - 5 months ago

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

Orchestra BioMed to Present at Upcoming Investor Conferences

Feb 20, 2025, 8:00 AM EST - 7 months ago

Orchestra BioMed to Present at Upcoming Investor Conferences

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Feb 18, 2025, 8:00 AM EST - 7 months ago

Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Feb 12, 2025, 10:43 AM EST - 7 months ago

Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Feb 5, 2025, 8:00 AM EST - 7 months ago

Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 26, 2024, 4:05 PM EST - 10 months ago

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Nov 12, 2024, 4:12 PM EST - 10 months ago

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug 12, 2024, 4:20 PM EDT - 1 year ago

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

May 22, 2024, 8:43 AM EDT - 1 year ago

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

May 13, 2024, 4:58 PM EDT - 1 year ago

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Mar 27, 2024, 4:17 PM EDT - 1 year ago

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

Orchestra BioMed to Participate in Upcoming Investor Conferences

Mar 7, 2024, 8:00 AM EST - 1 year ago

Orchestra BioMed to Participate in Upcoming Investor Conferences

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Mar 6, 2024, 8:37 AM EST - 1 year ago

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Jan 8, 2024, 7:30 AM EST - 1 year ago

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 13, 2023, 4:21 PM EST - 1 year ago

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Sep 19, 2023, 7:30 AM EDT - 2 years ago

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Aug 10, 2023, 4:34 PM EDT - 2 years ago

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Aug 8, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Jun 26, 2023, 8:00 AM EDT - 2 years ago

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Jun 7, 2023, 8:30 AM EDT - 2 years ago

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

May 12, 2023, 9:15 AM EDT - 2 years ago

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Feb 24, 2023, 8:00 AM EST - 2 years ago

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Jan 27, 2023, 8:00 AM EST - 2 years ago

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

Jul 5, 2022, 8:00 AM EDT - 3 years ago

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

j03j03j06
j03j03j06 Sep. 12 at 9:57 AM
$OBIO Im tired of this shit. Swing but shit moves recently bro.
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:16 PM
G101SPM 8/26/2025, 8:02:32 AM $OBIO $2.65 bid. DAC (4) $3.38 / last $2.75 (8.5.25). EXIT $7.00.
0 · Reply
G101SPM
G101SPM Sep. 9 at 2:59 PM
G101SPM 8/8/2025, 7:25:33 AM $OBIO $2.69 bid. DAC (dollar average cos) (4) $3.38 / last $2.75 (8.75 (8.5.25). EXIT $7.00.
0 · Reply
G101SPM
G101SPM Sep. 9 at 2:51 PM
G101SPM 8/5/2025, 7:15:52 AM $OBIO $2.75 ask. BUY/ADD 3X to long position carries SPM 84.97 tag to $7.00 in midterm. DAC (dollar average cost includes this BUY). (4) $3.28.
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 5 at 2:20 PM
$OBIO Great piece that accurately captures OBIO's current position. So if you want to refresh your understanding of OBIO or learn about OBIO for the first time, this is essential reading. https://beyondspx.com/quote/OBIO/orchestra-biomed-orchestrating-future-growth-through-breakthrough-technologies-and-strategic-alliances-nasdaq-obio#analysis
0 · Reply
estatebuyersmia
estatebuyersmia Sep. 5 at 10:54 AM
$OBIO REMEMBER IF ABCL OPENS ABOVE 4.20 WE ARE LOOKING AT A DEF MOVE TO 4.50. IF IT BREAKS 4.50, IT WILL TRY TO REACH 5.00
0 · Reply
sn0wball
sn0wball Sep. 5 at 10:53 AM
$OBIO https://finance.yahoo.com/news/orchestra-biomed-presents-avim-therapy-210000958.html
0 · Reply
BearishAlgo
BearishAlgo Sep. 4 at 11:19 PM
$OBIO
0 · Reply
YouVSYou
YouVSYou Sep. 4 at 11:02 PM
$TPVG tracking with $OBIO insider
0 · Reply
Love_To_Learn
Love_To_Learn Sep. 4 at 10:17 PM
$OBIO been tweaking u on and off latly
0 · Reply
YouVSYou
YouVSYou Sep. 4 at 9:10 PM
$OBIO massive insider buys
1 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Sep. 4 at 9:10 PM
$OBIO let her go to $3.00 no caution needed.... Let her go.. Let her go! 🚨🚨
0 · Reply
premarketmaker
premarketmaker Sep. 4 at 9:02 PM
caution - no buyers on the bid $OBIO
0 · Reply
BearishAlgo
BearishAlgo Sep. 4 at 9:01 PM
$OBIO approaching a key resistance area around $3.00- $3.20. Watching for a reaction here. If it breaks, I'd use this zone as support for a long position
0 · Reply
JarvisFlow
JarvisFlow Sep. 4 at 12:00 PM
HC Wainwright & Co. has adjusted their stance on Orchestra BioMed Hldgs ( $OBIO ), setting the rating to Buy with a target price of 12 → 10.
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Aug. 28 at 1:55 PM
$OBIO adds! Bounce over $3.00 soon I am wait.... 🚨🚨🚨🚨
0 · Reply
sirtweetie
sirtweetie Aug. 27 at 2:00 PM
$MBRX let's go baby! feels like a multi day runner; heavy consolidation, then we fly...watching $IXHL $OPEN $OBIO
1 · Reply
StayinOuttaTheRed
StayinOuttaTheRed Aug. 27 at 1:51 PM
$OBIO
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Aug. 27 at 1:41 PM
$OBIO adds!! No reason for this to be under $3.50🚨🚨
0 · Reply
PLATINUM_TRADES
PLATINUM_TRADES Aug. 27 at 12:12 AM
$OBIO broke that $2.90 resistance now $3.53 resistance from the end of July definitely possible now.... keeping it🚨🚨🚨🚨
1 · Reply
TheBearVsTheBull
TheBearVsTheBull Aug. 26 at 7:40 PM
$OBIO $LUCD $MDT $EXAS ORCHESTRA BIOMED AND LUCID DIAGNOSTICS ARE GOING TO BE THE TWO BIGGEST WINNERS COMING INTO Q4 -Q1 25-26 STAY TUNED PEOPLE!!!!!!!
0 · Reply
Fearrr
Fearrr Aug. 26 at 5:21 PM
$OBIO Over $3!!!
0 · Reply